|Bid||1.0600 x 800|
|Ask||1.1200 x 27000|
|Day's Range||1.0800 - 1.1000|
|52 Week Range||0.2000 - 4.3000|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Some Heat Biologics, Inc. (NASDAQ:HTBX) shareholders are probably rather concerned to see the share price fall 49...
COVID-19 vaccine stocks have easily been the hottest niche across the entire market since March. Developmental-stage companies like Inovio Pharmaceuticals (NASDAQ: INO), Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), Vaxart (NASDAQ: VXRT), and Heat Biologics (NASDAQ: HTBX) all saw their shares rise at a dizzying pace in 2020, thanks to their coronavirus vaccine candidates.
What happened Shares of the developmental biotech Heat Biologics (NASDAQ: HTBX) jumped by as much as 21% in pre-market trading Wednesday morning. The company's shares perked up in response to the release of a pre-print (a preliminary article that has yet to be peer-reviewed) discussing the animal data for its COVID-19 vaccine candidate.